meta
|
evidence
oncology
Living systematic review and meta-analysis
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
1
colorectal cancer (CRC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs regorafenib
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
PD-L1 < 1%
PD-L1 > 1%
RAS mutant
RAS wild type
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
SAE (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
Increased lipase level TRAE (grade 3-4)
hepatitis (Autoimmune) AE (grade 3-4)
Abdominal pain AE (grade 3-4)
Acute kidney injury AE (grade 3-4)
Anaemia AE (grade 3-4)
Arthralgia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Colitis AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Dermatitis acneiform AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dysgeusia AE (grade 3-4)
Dysphonia AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Guillain-Barré syndrome AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Increased ALT AE (grade 3-4)
Infusion-related reaction AE (grade 3-4)
Intestinal perforation AE (grade 3-4)
Mucosal inflammation AE (grade 3-4)
Myalgia AE (grade 3-4)
Nausea AE (grade 3-4)
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)
Peripheral neuropathy AE (grade 3-4)
Peripheral oedema AE (grade 3-4)
Pneumonitis AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Rash maculopapular AE (grade 3-4)
Sepsis AE (grade 3-4)
Stomatitis AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
Weight decreased AE (grade 3-4)
deaths (OS)
mCRC - 1st line (L1)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
mCRC - 2nd line (L2)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 2nd line (L2)
versus regorafenib
atezolizumab alone vs. regorafenib
1
certainty unassessable
0%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open